BioAge Labs, Inc. (NASDAQ: BIOA)
58 Days left to seek lead plaintiff status.
The Complaint alleges that Plaintiff and the class bought BioAge stock in the initial public offering based on false and/or materially misleading information concerning its STRIDES Phase 2 clinical trial and that these investors sustained damages as a result thereof.